The E6 proteins originating from the tumour-associated Human Papillomavirus (HPV) types 16 and 18 have been shown to bind to and target the tumour suppressor protein, p53, for ubiquitin-mediated degradation. However, in cell lines derived from cervical neoplasias, the predominant early region transcripts are spliced and encode truncated forms of E6, termed E6*. We report here that HPV-18 E6* protein will interact both with the full-length E6 proteins from HPV-16 and HPV-18 and also with E6-AP, and subsequently blocks the association of full length E6 protein with p53. We also show that, as a result of this block, E6* can inhibit E6-mediated degradation of p53 both in vitro and in vivo. The biological consequences of this are increased transcriptional activity on p53-responsive promoters and an inhibition of cell growth in cells transfected with E6*. This is the ®rst report of a potential biological function for this polypeptide and may represent a means by which HPV is able to modulate the activity of the full-length E6 protein with respect to p53 during viral infection.
Introduction
Human Papillomaviruses (HPVs) are a group of strongly epitheliotropic small DNA viruses, a subset of which infect the anogenital mucosa. Of this subset some HPV types, such as 6 and 11, are found associated with benign lesions whereas other types, such as 16 and 18, are commonly associated with lesions that can progress to high-grade cervical intraepithelial neoplasia and ultimately to cervical cancer (zur Hausen and Schneider, 1987) . The early viral proteins E6 and E7 are continually expressed in cell lines derived from cervical tumours (Smotkin and Wettstein, 1986; Androphy et al., 1987; Banks et al., 1987) . They interact with key cellular tumour suppressors; E7 with pRb (Dyson et al., 1989) and E6 with p53 , and can cooperate to immortalise primary human keratinocytes (Barbosa and Schlegel, 1989; Hawley-Nelson et al., 1989; Munger et al., 1989) . These ®ndings are considered to be central to the role of these HPVs as initiators of tumourigenesis, and infection of cervical keratinocytes by these`high-risk' HPVs can therefore be said to predispose them to immortalisation and subsequent progression to malignancy.
In contrast to the simple monocistronic mRNAs which encode E6 and E7 from the non oncogenic HPVs (Chow et al., 1987; Smotkin et al., 1989) , the splicing pattern for the early viral transcripts of the oncogenic types, such as HPV-16 and HPV-18, is complex. These HPVs produce not only bi-cistronic mRNAs for E6 and E7, but also alternatively spliced mRNAs from which a large portion of E6 has been removed, with the mRNA splicing back into a dierent reading frame before reaching an adjacent termination codon. These alternatively spliced species are termed E6* and form the majority of early viral transcripts both in cervical tumours and in tumour-derived celllines (Schneider-GaÈ dicke and Schwarz, 1986; Smotkin and Wettstein, 1986) . Indeed in many tumours, transcripts for unspliced, full-length E6 are in extremely low abundance (Doorbar et al., 1990; Bohm et al., 1993; Grassmann et al., 1996) . It was originally proposed that these splicing events increased the translation eciency for the E7 open reading frame by increasing the inter-cistronic spacing between E6 and E7 (Sedman et al., 1991) . However, recent studies have demonstrated that E7 is, in fact, as eciently translated from E6-E7 bicistronic mRNA as it is from spliced transcripts (Stacey et al., 1995) and that mutation of the splice donor site in E6 has no eect upon the levels of PCNA induced by E7 in dierentiating keratinocytes (Cheng et al., 1995) . These results imply that the splicing of E6 mRNA may have a dierent purpose. In addition, monoclonal antibodies made against a peptide derived from a putative HPV-18 E6* protein identi®ed a protein of the predicted molecular weight in nuclear extracts of HPV-18 containing human tumour cells which had been grown in nude mice (Schneider-Gadicke et al., 1988) . Interestingly, this same protein was not found in extracts from HPV-containing cell lines originally derived from cervical tumours, even though E6* mRNA is the majority species found in these lines (Schneider-GaÈ dicke et al., 1988) .
Since the potential to encode E6* proteins is a property of only the tumour-associated HPV types, considerable eort has been expended in attempting to demonstrate that E6* proteins possess a transforming activity. These studies in fact demonstrate the reverse, in that coexpression of E6* with E6 and E7 in primary human keratinocytes produces substantially fewer immortalised colonies than those obtained in the absence of E6* (Sedman et al., 1991) . Previous studies have demonstrated some potential transcriptional transactivating activity for a form of E6* (E6*I) derived from HPV-16 (Shirasawa et al., 1994) . In addition, a recent study demonstrated that the E6*IV form of E6* from HPV-16 was able to inhibit E6 directed degradation of p53 in vitro (Shally et al., 1996) . However, the work described here is the ®rst demonstration of a potential biological function for an E6* protein derived from HPV-18. Our aim in these studies was to investigate the potential of HPV-18 E6* protein to modulate the most widely studied property of the full-length E6 protein, that of its interaction with the cellular tumour-suppressor protein p53. HPV-18 E6, like HPV-16 E6, interacts with p53 via a cellular intermediate termed E6-AP and causes p53 to become ubiquitinated and degraded along the ubiquitin pathway (Schener et al., 1990 Huibregtse et al., 1991) . In this study we have been able to demonstrate that HPV-18 E6* can bind to E6-AP and to both fulllength HPV-18 and HPV-16 E6 proteins in vitro. As a consequence of these interactions E6* protein can prevent full-length HPV-18 E6 from binding to p53 protein and targeting it for ubiquitin-mediated degradation both in vitro and in vivo. We also show that transfection of E6*-expressing constructs into cells derived from cervical tumours results in a marked induction of p53 transcriptional activity, consistent with its protection from E6 induced degradation. Finally, we show that a potential consequence of this increased transcriptional activity of p53 in E6* transfected cells, which harbour HPV DNA sequences, is a decrease in transformed cell growth. These results demonstrate that control of the E6 to E6* ratio during normal viral infection may have a profound eect on the fate of p53 protein and hence upon the fate of the infected cell.
Results

HPV-18 E6* binds to the full-length HPV-18 and HPV-16 E6 proteins
Previous studies have shown that the full-length HPV-18 E6 protein associates with p53 as part of a 40 kd complex (Medcalf and Milner, 1993) , consistent with the notion that E6 may associate with p53 as a dimer. Indeed, we have noted that E6 binds to itself with a high eciency in in vitro association assays (D Pim, personal observations). We were therefore interested in determining whether E6* protein could heterodimerise with the full-length E6 protein. The structure of the HPV-18 E6* we have used with respect to splice donor and acceptor sites has already been ascertained (Schneider-GaÈ dicke and Schwarz, 1986) and is shown in Figure 1 . This represents the only HPV-18 E6* protein shown to be expressed in vivo and was therefore chosen for our studies. Using this information, we designed a set of oligonucleotides to amplify the E6* DNA from the HPV-18 E6 open reading frame and clone it into pGEX2T. For comparative purposes we also produced a GST fusion protein of the full length HPV-18 E6. These proteins were expressed and puri®ed and the pro®les obtained are shown in the upper panel of Figure 2 . We then investigated the ability of the GST-E6* to bind to in vitro translated HPV-18 and HPV-16 E6 proteins. As an additional control we also included HPV-16 E7 which has some sequence similarity with E6 since HPV-16 E7 contains a similar CysXXCys motif in its carboxy terminus. The results obtained are shown in Figure 2 . As expected, GST-18E6 eciently retained in vitro translated HPV-18 E6 protein. However, signi®cant binding of both HPV-18 and HPV-16 E6 proteins was observed on the GST-E6* column compared with the GST column. In contrast minimal retention of E7 protein was obtained on the GST E6* column and this supports the speci®city of the binding assay. These results demonstrate that HPV-18 E6* can heterodimerise with the full length E6 proteins of both HPV-16 and HPV-18.
HPV-18 E6* blocks the interaction of full-length E6 with p53 in vitro Having demonstrated that E6* and E6 can heterodimerise, we wished to investigate the possibility that such a complex might block the interaction of fulllength E6 with p53, since it has already been demonstrated that multiple domains of E6 are involved in its association with p53 (Crook et al., 1991; Pim et al., 1994; Thomas et al., 1995) . To do this, we ®rst pre-incubated GST-18 E6 with in vitro translated, radiolabelled E6* protein prior to addition of in vitro translated, radiolabelled p53. The results obtained are shown in Figure 3a , and demonstrate that E6* can reduce p53's binding to GST-18 E6. We then performed the converse experiment pre-incubating in vitro translated, radiolabelled 18 E6 with in vitro translated, radiolabelled E6* prior to addition of GST-p53. As a control for this experiment we included in vitro translated HPV-16 E1 protein. The results obtained are shown in Figure 3b . The right hand panel shows the protein inputs used for this In contrast, addition of E1 protein has no eect upon the interaction between E6 and p53, and this demonstrates the speci®city with which E6* inhibits the association between E6 and p53.
HPV-18 E6* inhibits the full-length HPV-18 E6-directed degradation of p53 both in vitro and in vivo Since E6* can inhibit the binding of HPV-18 E6 to p53 it also seemed likely that it might block E6-directed degradation of p53. To investigate this possibility, in vitro translated p53 was incubated at 308C with in vitro translated full-length HPV-18 E6 for 30 min in the presence or absence of in vitro translated E6*. The results are shown in Figure 4 . It is clear that almost complete degradation of p53 occurs in the presence of HPV-18 E6, while E6* alone does not reduce the amount of p53 protein present. In fact the addition of increasing amounts of E6* progressively blocks the E6 directed degradation of p53. To investigate further the speci®city of this activity of E6* the assay was also performed with in vitro translated E7 protein. The results obtained are also shown in Figure 4 and demonstrate that E7 has no eect upon E6 induced degradation of p53.
Having shown that E6* will inhibit E6 induced degradation of p53 we were further interested in the mechanisms by which this occurs. Obviously dimerisation with the full length E6 protein may represent one possible mechanism, however we also felt it to be important to assess the ability of E6* to bind the p53 and E6-AP proteins which may represent other means by which it mediates its activity. To do this we investigated the ability of in vitro translated p53 and E6-AP to bind to GST-E6* and GST-18E6 proteins. The results obtained are shown in Figure 5 . It is clear that, in comparison to the full length E6 protein, E6* only binds very weakly to p53. This agrees with previous studies (Shally et al., 1996) and would appear
Figure 3 HPV-18 E6* blocks the interaction between full-length HPV-18 E6 and p53. (a) Increasing quantities of E6* inhibit p53 binding to GST-18E6. 1 ml of in vitro translated radiolabelled p53 was bound to GST and to GST-18E6 with or without preincubation of the fusion protein with 5 ml and 10 ml of in vitro translated E6*. Bound p53 protein was detected following Page and autoradiography. (b) Increasing quantities of E6* inhibit 18 E6 binding to GST-p53. 1 ml of in vitro translated radiolabelled HPV-18 E6 was bound to GST and to GST-p53 with or without preincubation of the HPV-18 E6 with 2 ml and 5 ml of in vitro translated, radiolabelled E6* or 5 ml of HPV-16 E1. Bound HPV-18 E6 protein was detected following Page and autoradiography. The right hand panel shows the input proteins used for the binding assay HPV-18 E6* inhibits HPV-18 E6 directed degradation of p53 in vitro. Equal amounts of p53 were incubated for 30 min at 308C with water primed lysate (Lane 1), 2 ml of in vitro translated HPV-18 E6 (Lane 2), 10 ml of HPV-18 E6* (Lane 3), 2 ml of HPV-18 E6 plus 5 ml of E6* (Lane 4), 2 ml of HPV-18 E6 plus 10 ml of E6* (Lane 5) and 2 ml of HPV-18 E6 plus 10 ml of HPV-16 E7 (Lane 6). Having demonstrated that E6* can block E6-directed degradation of p53 in vitro, we were then interested in determining if the same was true in vivo. In order to investigate this, we performed a series of in vivo E6-directed degradation assays. p53-null (10)1 mouse cells and p53-null Saos-2 human cells were transfected with plasmids expressing p53, HPV-18 E6 and HPV-18 E6*. After 24 h cell extracts were made and p53 protein levels were ascertained by Western blot analysis using a pool of the anti-p53 antibodies pAb1801, 1802 and 1803 (Banks et al., 1986) . The results obtained are shown in Figure 6 . Transfection of p53 expression plasmid alone produces high level p53 expression which consists of the full length protein together with some lower molecular weight proteins which most probably represent breakdown products of the protein. It is clear that the cotransfection of constructs expressing HPV-18 E6 and p53 results in a signi®cant decrease in the level of p53 protein detected in each cell line, and demonstrates that E6 will induce degradation of human p53 in cells of human and, to a lesser extent, of mouse origin. Most signi®cantly, cotransfection of a construct expressing E6* results in a marked increase in the levels of p53 detectable in both cell lines, and con®rms that E6* protein protects p53 from E6-directed degradation both in vitro and in vivo.
HPV-18 E6* increases the transcription from promoters containing a p53-responsive element One of the most obvious potential consequences of p53 stabilisation in response to E6*'s interference with E6 mediated degradation of p53, is an increase in p53 transcriptional activity. To investigate whether the induced p53 is transcriptionally active, we performed a series of CAT assays in two cell lines derived from cervical tumours, using a p53 responsive reporter plasmid. CaSki cells contain HPV-16 DNA sequences and HeLa cells contain HPV-18 DNA sequences. Both lines continue to express E6 protein Banks et al., 1987) , and have low levels of wild type, transcriptionally competent, p53 (Butz et al., 1995) ; although the level to which p53 can be activated is much lower in HeLa than in CaSki cells (Butz et al., 1995) . To investigate the eects of E6* expression on p53 transcriptional activity, CaSki and HeLa cells were transfected with a reporter construct containing the mdm2 promoter upstream of a CAT gene (Barak et al., 1994) together with either vector alone or plasmids containing full length HPV-18 E6 or HPV-18 E6*. The results obtained are shown in Figure 7a and b. As reported previously (Butz et al., 1995) , transfection of a p53 responsive plasmid into CaSki cells results in a modest activation, consistent with there being a low but nonetheless functional level of p53 protein in these cells; cotransfection of HPV-18 E6 further reduces the level of p53 transcriptional activity. Similar results are also seen in HeLa cells, but at a much lower level, and this is in agreement with previous studies (Butz et al., 1995) . In contrast, cotransfection of HPV-18 E6* into either cell line results in a substantial increase in p53 transcriptional activity. These results are consistent with the above data which indicate that E6* protein induces the accumulation of functional p53 protein by inhibiting the activity of the full length E6 protein. To investigate whether the induction of p53 transcriptional activity by E6* was due entirely to inhibition of E6 function, we repeated this series of assays in HT1080 cells which possess wild type p53 protein but lack any Figure 7c . As expected, transfection of vector alone gives rise to high levels of p53 transcriptional activity which is subsequently inhibited by HPV-18 E6. Transfection of E6* results in a slight rise in p53 transcriptional activity compared with control transfected cells. Clearly, the level of increase in p53 transcription is much less than that seen in CaSki cells, indicating that the main route by which E6* increases p53 mediated transcription is by interfering with the function of the full length E6 protein.
However, these results also indicate that E6* has the potential to induce p53 transcriptional activity through a pathway not solely due to that of binding and inhibiting E6 function. Previous reports had indicated that E6* may have an intrinsic transcriptional activity on the Adenovirus E2 promoter (Shirasawa et al., 1994) . To investigate this further, p53 null 10(1) mouse cells were transfected with E6* expression plasmid together with either a Adenovirus E2 promoter CAT plasmid or the p53 responsive CAT plasmid. The results obtained are shown in Figure 8 and demonstrate that E6* has no intrinsic transcriptional activity on either the Adenovirus E2 promoter or the p53 responsive promoter. We have never observed any detectable eect of HPV-18 E6 on the mdm2CAT reporter construct in the absence of p53 (data not shown).
HPV-18 E6* can increase the growth arrest function of p53 in cells expressing HPV-16 E6
Previous studies have shown that induction of p53 transcriptional activity correlates with its ability to either suppress cell growth or induce apoptosis (Kern et al., 1992; Kessis et al., 1993; Pietenpol et al., 1994; Wu and Levine, 1994; Thomas et al., 1996a) . In the light of the above experiments we were therefore particularly interested in determining what eects exogenously expressed E6* protein would have upon the proliferative capacity of CaSki cells. In order to investigate this, CaSki cells were transfected with plasmid pcDNA3 expressing either p53, full-length HPV-18 E6 or HPV-18 E6*. In addition, similar transfections were also performed in p53 null 10(1) cells, Saos-2 cells and HT1080 cells. The cells were then placed under G418 selection for 2 weeks before ®xing and staining. The numbers of G418-resistant colonies were counted and the results are shown in Figure 9 . As reported previously, transfection of p53 into cells derived from cervical tumours results in a marked inhibition of cell growth, through a mechanism which consists largely of induction of apoptosis (Haupt et al., 1995) . Similarly, p53 produces a dramatic decrease in colony formation in Saos-2, 10(1) and HT1080 cells. Transfection of additional HPV E6 protein into these cells results in minimal changes in the number of proliferating colonies compared with control transfected cells. Strikingly, transfection of E6* results in a clear inhibition of colony formation in CaSki cells in a manner similar to that seen with p53 transfection. In contrast, E6* has no inhibitory eect in either the 10(1), Saos-2 or HT1080 cells. This result demonstrates that the eects of E6* in CaSki cells are not due to a general cytotoxicity. Rather, these results show that an 
Discussion
In this study we have performed the ®rst extensive analysis of the potential functions of the HPV-18 E6* protein. Previous investigations have focused on the potential of E6* protein to act in a positive fashion in immortalisation assays, either alone or in cooperation with the full length E6 and E7 proteins. These studies showed that E6* did not increase the frequency with which immortalised cells were produced, but rather, seemed to have the opposite eect (Sedman et al., 1991) . The recent studies which showed that the spliced mRNA which encodes E6* protein did not increase E7 expression (Stacey et al., 1995; Cheng et al., 1995) , prompted us to investigate further the possible activities of the E6* protein itself. First, we showed that the HPV-18 E6* protein can form heterodimers with the full length E6 proteins derived from both HPV-16 and HPV-18; this is not surprising, bearing in mind the high degree of functional conservation between the HPV-16 and 18 E6 proteins. Previous studies had shown that the complex of E6 and p53 consists of p53 tetramers plus complexes of E6 with a molecular weight consistent with their being dimers (Medcalf and Milner, 1993) and several reports have also indicated that both the amino terminal and carboxy terminal regions of the E6 protein are involved in the interaction with p53 (Crook et al., 1991; Pim et al., 1994) . We reasoned therefore, that binding of the E6* protein to the full length form of E6 would inhibit its association with p53. Indeed preincubation of E6* with HPV-18 E6 protein markedly inhibits its ability to complex with p53. However the situation is not as simple as it may at ®rst seem.
Alternative mechanisms of E6* activity were suggested to be through E6* binding to either p53 or E6-AP. Our results demonstrate no signi®cant binding between E6* and p53 and this would appear to preclude this as a means by which E6* could protect p53 from E6 directed degradation. Most interestingly, we found that E6* binds strongly to the E6-AP protein, at levels similar to those seen with the full length E6 protein. This indicates, therefore, an alternative mechanism by which E6*'s activity may be mediated. These studies are in agreement with previous reports which have shown that mutations within the carboxy terminal half of E6 abolish binding to p53 (Crook et al., 1991) , indicating that the principal amino acids involved in complexing p53 are absent in E6*. In contrast, mutants of E6 in the amino terminal region retain p53 binding but are defective in their ability to label p53 for ubiquitin mediated degradation (Crook et al., 1991; Pim et al., 1994) . This is consistent with the notion that the amino terminal region of E6 binds to E6-AP and our studies with E6* support this conclusion. Studies involving mutational analysis of E6* are currently in progress to ascertain whether E6*'s dimerisation with full length E6 protein or alternatively, its binding to E6-AP, is the principal means by which E6* functions. This may be quite complex since there appear to be sequences present within both the amino and carboxy terminal regions of the full length E6 protein which contribute to dimerisation (L Banks, personal observations).
Having shown that E6* inhibits binding between E6 and p53, we also found that this inhibition results in a reduction in the ability of HPV-18 E6 to label p53 for ubiquitin mediated degradation, both in vitro and in vivo. In agreement with our studies, Shally et al. (1996) reported that bacterially expressed HPV-16 E6*I protein could also inhibit full length E6 mediated degradation of p53. It therefore seems likely that splicing of the E6 mRNA and expression of an E6* protein represents a common mechanism whereby the association of E6 with p53 is regulated.
We then argued that protection of p53, by E6*, from E6 directed degradation might result in an increase in p53 mediated transcriptional activity. To investigate this we transfected constructs expressing E6* and wild type p53 into CaSki and HeLa cells which contain HPV-16 E6 and HPV-18 E6 respectively. In agreement with our in vitro binding and in vivo degradation assays, expression of E6* resulted in a marked increase in p53's transcriptional activity in both cell lines, consistent with the notion that E6* was interfering with full length E6 mediated degradation of p53 in these cells. As a control for these experiments, we also analysed the activity of E6* with respect to p53 transcriptional activity in cells which lack E6 sequences. In this case, a slight increase in p53 transcriptional activity was observed. These results indicate that the main role of E6* in relation to p53 is its protection from degradation by the full length E6 protein. However, it is also likely that E6* can induce p53 transcriptional activity in the absence of full length E6 protein and studies are currently in progress to de®ne this activity further. At the same time we also investigated the ability of E6* to activate the Adenovirus E2 promoter and the p53 responsive mdm2 promoter, since there are con¯icting reports concerning the potential of E6* to activate the Adenovirus E2 promoter (Sedman et al., 1991; Shirasawa et al., 1994) . In our studies E6* had no signi®cant eect upon the expression levels of either promoter.
Previous studies have shown that induction of p53 transcriptional activity results in the induction of cell growth arrest and/or apoptosis (Kern et al., 1992; Kessis et al., 1993; Pietenpol et al., 1994; Wu and Levine, 1994; Thomas et al., 1996a) . Obviously, it was of interest to determine whether the induction of p53 transcriptional activity by E6* in the CaSki cells would reduce cell proliferation. Cells were transfected with plasmids expressing E6*, p53 and full length E6 and, following G418 selection, an assessment of the proliferative capacity of the cells was obtained from the number of G418 resistant colonies obtained. The results obtained are clear and show that E6* inhibits the proliferation of CaSki cells in a manner similar to that seen with p53. In contrast no inhibition of cell growth was obtained in cells lacking p53 protein (Saos-2 and 10(1)), nor in cells containing wild type p53 protein but no HPV DNA sequences (HT1080). These results demonstrate that the HPV-18 E6* protein can suppress transformed cell growth in cells derived from cervical tumours which contain wild type p53 and E6 protein.
HPVs, unlike lytic viruses such as SV40 and Adenovirus type 5, have relatively long life cycles.
Nevertheless, like SV40 and Adenovirus, they have evolved to gain some advantage from the interaction of their early proteins with the cellular tumour suppressors p53 and pRb (Dyson et al., 1989; Werness et al., 1990) . It has been suggested that the result of the E6-p53 interaction is the rapid degradation of p53 along the ubiquitin pathway, and that this has the same net eect as abolition of p53 function by mutation. The results of p53 mutation, however, frequently give rise to cellular immortalisation and malignancy as shown by the long-term survival of p53-null mice (Donehower et al., 1992) , and the high frequency of cancers in LiFraumeni families (Vogelstein, 1990) . Whilst earlier ideas on HPVs and cervical cancer suggested that cell immortalisation resulted from integration of the viral DNA into the host chromosomes, there is increasing evidence that the virus can immortalise the host cell whilst still remaining episomal, and that integration occurs as a later event (Jeon and Lambert, 1995) . HPVs must therefore tread a ®ne line between exploiting the advantage they gain from their E6-p53 interaction and the risk of immortalisation, since this will result in a loss of replicative competence. This concept of a balanced host-virus relationship is supported by the relative scarcity of full-length E6 transcripts in cervical tumour cells of HPV origin, and by the observation that cell lines derived from such cervical tumours commonly retain wild-type p53 (albeit at low levels) which in many cases can still be induced by DNA damaging agents (Butz et al., 1995) . The evidence implies that the function of full-length E6 needs to be controlled to avoid immortalisation. Control of the quantities of E6 transcripts and their stability (Jeon and Lambert, 1995) appears to be one such method, and we present in this study a second potential control whereby E6* protein can modulate the function of the full-length E6 protein. It has been suggested that the failure to detect E6* protein in tumour-derived cervical cell lines is perhaps due to a short half-life in these cells (Sedman et al., 1991) . However, if this is true, such a short half-life would appear to be no barrier to function since heterologous expression of E6* protein in CaSki cells reduces their proliferation. The observation that E6* appears to be expressed in HPV-18 derived cervical tumour cells grown in nude mice (Schneider-GaÈ dicke et al., 1988) , implies that this protein may be translated only under very tightly controlled conditions, which might be expected of a protein whose function is to elevate the growth control capacity of p53 in infected cells.
In conclusion, we have shown that the HPV-18 E6* protein will protect p53 from E6 directed degradation and that this results in suppression of transformed cell growth. These studies provide evidence of a complex balance between the viral E6 proteins and the cellular tumour suppressor p53.
Materials and methods
Cell lines
Saos-2 p53-null human osteosarcoma cells, p53-null 10(1) mouse cells, HeLa cells, CaSki cells and HT1080 human ®brosarcoma cells, were grown and maintained in DMEM (Gibco) supplemented with 10% foetal calf serum
Plasmid constructs and in vitro translations
The open reading frame (ORF) for HPV-18 E6* was cloned from a plasmid construct containing full-length HPV-18 E6, by a modi®cation of the PCR mutagenesis system. Brie¯y, one round of ampli®cation was performed to obtain the ORF in two parts, the ®rst from the 5' end to the splice donor site, and the second from the splice acceptor site to the 3' end, using 5' and 3'¯anking oligos and a pair of internal, partially overlapping oligos. The products from the ®rst round of ampli®cation were puri®ed through low-melting point agarose, then combined for a second round of ampli®cation, using only the¯anking oligos, to obtain a full-length E6* which was then cloned in-frame into the SmaI/EcoRI sites of expression vector pGEX2T for bacterial expression as a GST fusion protein; into pSP64 for in vitro translation; or into eukaryotic expression vectors pJ4O and pcDNA3 (Invitrogen). The cloning of p53 into pGEX2T has already been described (Massimi et al., 1996) as has the cloning of HPV-18 E6 into pGEX2T (Thomas et al., 1996b) .
For in vitro translation the open reading frames for HPV-18 E6, HPV-16 E6, HPV-16 E7, HPV-16 E1 (Storey et al., 1995) and a 95 kDa clone of E6-AP were cloned in pSP64. Proteins were translated using the Promega TNT system.
Production and puri®cation of GST-fusion proteins
Bacteria containing GST constructs were diluted into 50 mls of Luria broth from overnight cultures, grown 1 h at 378C with shaking, then IPTG was added to 1 mM and the cultures grown for a further 2 h. The bacteria were centrifuged and the pellets were resuspended in 500 ml of ice cold PBS containing Triton X-100 to 1%, then sonicated on ice for 30 s. The lysates were then clari®ed by centrifugation and the supernatants removed. Fusion proteins were puri®ed from the lysates by mixing with Glutathione agarose beads (Sigma) at 48C for 30 min, then washing three times with cold PBS/1% Triton X-100. Protein purity was monitored by Page and Coomassie blue staining.
In vitro binding assays
For the initial binding reaction, GST-fusion proteins bound on Glutathione agarose were washed 36 in cold PBS to remove the Triton X-100 used during puri®cation, then binding assays performed in a buer containing 150 mM NaCl, 5 mM EDTA, 50 mM Tris pH 7.5, 0.05% NP40, 0.25% gelatin and 2 mg ml/1 BSA. In vitro translated proteins were added and incubated with the fusion proteins 2 h at room temperature, then the agarose beads washed once in the same buer; then 46 in PBS/1% NP40. For competitive binding assays involving in vitro translated E6*, fusion proteins bound on Glutathione agarose beads were washed in PBS before addition of in vitro translated proteins. Incubations were performed for 1 h on ice, and washes done 36 in cold PBS/0.5% NP40, and bound proteins visualised by PAGE and autoradiography.
In vitro degradation assays
In vitro degradation assays were performed as described previously (Pim et al., 1994) .
In vivo degradation assays
Saos-2 cells and p53-null 10(1) cells were transfected with constructs expressing p53, HPV-18 E6 and E6* by calcium phosphate-mediated DNA transfer. After 24 h, cells were harvested in extraction buer containing 250 mM NaCl, 0.1% NP40, 50 mM HEPES pH 7.0 and 1% Aprotinin. Proteins were separated by PAGE and then transferred to nitrocellulose. The blot was probed with a cocktail of the mouse anti-p53 monoclonal antibodies, pAb1801, 1802 and 1803, (Banks et al., 1986) followed by anti-mouse biotin conjugate (Dako), and avidin-peroxidase (Dako), before developing with the Amersham ECL detection system according to the manufacturer's instructions.
CAT assays
CaSki or HT1080 cells were plated out on 60 mm petri dishes at 1610 5 cells per dish and transfections were carried out by calcium phosphate mediated DNA transfer. 5 mg of the mdm2 CAT reporter plasmid p(mdm2)NA-CAT (Barak et al., 1994) were transfected together with combinations of pJ4O18E6, pJ4O p53 and pJ4OE6* as indicated in the text. Cells were harvested after 48 h and processed as described previously (Pim et al., 1994) . Transfection eciencies were monitored by cotransfecting the b-galactosidase expression plasmid pCH1101 onto parallel plates. Standard deviations were calculated from a minimum of four separate experiments.
Cell proliferation assays
CaSki cells were plated out at a density of 3610 5 per 90 mm petri dish and transfected with 10 mg of either HPV-18 E6, HPV-18 E6* or p53 in plasmid pcDNA3 (Invitrogen) by calcium phosphate mediated DNA transfer. After glycerol shock, cells were grown under selection with G418 at 200 mg ml 71 for 2 weeks. After this time, cells were ®xed with 10% formaldehyde, stained with 10% Giemsa and colonies counted.
